A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants
Completed · Phase 1
Conditions studied: Healthy Volunteers
In brief
The purpose of this study is to determine the absorption, metabolism, and excretion of \[14C\]-BGB-16673 and to characterize and determine, where possible, the metabolites present in plasma, urine, and feces in healthy male participants following a single oral administration.
Key facts
- Study ID
- NCT06776679
- Run by
- BeiGene
- People needed
- 8
- Starts
- 2025-01-24
- Expected to finish
- 2025-03-27
- Last updated by the study team
- 2025-05-01
Who can join
Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.
You may qualify if…
- Body mass index between 18.0 and 32.0 kg/m², inclusive.
- Good health, as determined by no clinically significant findings from medical history.
- History of a minimum of 1 bowel movement per day.
- Able to comprehend and are willing to sign the Informed Consent Form (ICF) and abide by the study restrictions.
You may not qualify if…
- Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
- Confirmed systolic blood pressure >140 or <90 mmHg, diastolic blood pressure >90 or <50 mmHg, or pulse rate >100 or <40 beats per minute.
- Alcohol consumption of >21 units per week for males.
- Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.
- Ingestion of caffeine-containing foods or beverages within 48 hours of check-in or intend to ingest caffeine-containing foods or beverages until end of study.
- Use of tobacco- or nicotine-containing products within 3 months prior to check-in, or positive cotinine at screening or check-in.
- Ingestion of Seville orange- or grapefruit-containing foods or beverages within 7 days prior to check-in.
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Where it is running
- Fortrea Clinical Research Unit Inc — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.